Research and clinical trials

Dietary strategies that change the gut microbiome are of interest because they might modify inflammation without drugs. This study suggests PEN+ED can shift the microbiome toward a healthier profile in UC, though...

Mitochondrial dysfunction may be a central contributor to UC inflammation and is being targeted by new therapeutic strategies that could lead to different treatment approaches in the future.

The findings suggest that over three decades more patients receive medical prevention after ileocolic resection — including thiopurines and biologics — and that rates of needing a second surgery have fallen. This matters...

Shows real-world long-term outcomes in a large Chinese UC cohort and highlights that baseline disease activity predicts need for escalation and colectomy risk; points to opportunities to improve treat-to-target care.

Based on the title and source metadata, this appears to be a basic science related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Toxicology Mechanisms...

This study suggests the cancer drug lapatinib reduced colon damage and liver changes in a rat model of chemical colitis, which could point to new research directions for IBD treatments or gut–liver injury mechanisms.

Malassezia extracellular vesicles can modulate immune and microbial interactions; if similar mechanisms affect the gut, they could be relevant to inflammatory bowel disease and Crohn’s disease, though current evidence is...

Respiratory diseases (COPD, asthma, bronchiectasis) and IBD appear to occur together more often than expected. If you have IBD, especially Crohn’s, you may be at higher risk for some obstructive lung diseases, and people...

If environmental microplastics contribute to gut dysbiosis and mucosal inflammation, this could help explain environmental triggers of ulcerative colitis and point toward prevention or microbiome-targeted interventions.

Researchers used a standard mouse colitis model to show a traditional herbal formula reduced inflammation and improved gut barrier markers, implicating the IL-33/ST2 immune pathway. This could guide future preclinical...

People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...

The study identifies candidate metabolites that may underlie gut–brain biochemical crosstalk during colitis, which could point to early biomarkers or mechanistic targets relevant to IBD-related brain effects.

The study identifies a cellular mechanism by which arctigenin reduced inflammatory macrophage death and improved colitis in mice, suggesting a potential new target (macrophage FAO → GSDMD) for therapies or...

A coordinated national research network can accelerate studies that matter to people with IBD—like tracking real-world disease patterns, testing diet and psychosocial approaches, improving monitoring with biomarkers and...

If true, a common gut microbe (Fusobacterium nucleatum) and its metabolite succinic acid could worsen intestinal inflammation by changing macrophage behavior, suggesting new targets to reduce flares or mucosal injury in...

This study synthesizes randomized trial evidence about the role of gut microbiota in ulcerative colitis and whether fecal microbiota transplantation (FMT) can help induce remission. People with UC may encounter FMT as a...

The study suggests dietary tryptophan might reduce bacterial-induced acute lung injury in the context of colitis by altering gut–lung immune signaling, which could be relevant to IBD patients who are at risk for...

This study identifies molecular targets and organoid-based effects of ganoderic acid A on inflammatory pathways relevant to IBD, pointing to a potential multi-target avenue for future drug-discovery research.

This registry will provide real-world data on how etrasimod is used and performs in routine clinical practice in China, including patient characteristics, symptom trajectories, safety, and healthcare costs. Real-world...

This trial is testing duvakitug as a maintenance treatment for people with moderately to severely active ulcerative colitis who responded to an earlier study, which could expand treatment options if later shown to be...

People with IBD often look for safe, low-cost adjuncts to medical therapy. This review compiles mechanisms by which dietary polysaccharides could support gut barrier function, beneficial microbes, and anti-inflammatory...

People with Crohn’s disease facing surgery may have varying risks of complications; better biomarkers and models could help tailor perioperative care and decision-making. The review signals active research toward more...

JAK1 inhibitors are an established therapeutic pathway in IBD; new, more selective small molecules could expand future treatment options. This study reports a novel compound with strong preclinical activity against...

AI tools are being tested to speed capsule endoscopy reading and help triage cases, which matters to people with IBD because capsule endoscopy is commonly used to detect small-bowel ulcers and inflammation.

People with IBD face an elevated lifetime risk of colitis-associated cancer; improved detection and risk prediction could lead to earlier treatment and better outcomes. AI could make surveillance more accurate and...

The work links intestinal inflammation with neurobehavioral changes in a mouse colitis model and suggests certain p‑coumaric acid derivatives can reduce inflammation and anxiety/depression‑like behaviors, which could...

This preclinical study suggests a fermented postbiotic product may protect the colon in a mouse model of ulcerative colitis by altering the microbiome and tryptophan metabolites and by reducing ferroptotic cell death....

The study presents a mitochondria-targeted compound that reduced necrosis markers, HMGB1, and IL-1β in cell and mouse colitis models, highlighting a potential new pathway for IBD treatment research.

This study describes a new nanozyme approach that reduced inflammation and shifted the gut microbiome in mouse colitis models, suggesting a potential future strategy to boost probiotic therapy for IBD by targeting...

The study suggests that a physician-endorsed, librarian-developed information prescription may improve quality of life and reduce short-term relapse in people with IBD, a non-pharmacological approach that could be...

Diet is a modifiable factor that appears to change the gut microbiome and may affect symptoms and inflammation in both IBS and IBD; understanding which patterns help could guide practical dietary advice.

The study maps how two ginger preparations differently affect metabolism and the gut microbiome in a mouse model of ulcerative colitis, which could inform more targeted use of ginger-derived treatments if findings are...

People with ulcerative colitis commonly experience depression; understanding whether the relationship is causal and which blood proteins might mediate it could help researchers develop biomarkers or new therapies...

Researchers are exploring plant-based formulas for inflammation beyond the gut. If the SGD effects translate to humans, it could point to new ways to prevent or treat liver injury that can accompany active UC by...

The paper identifies Candida albicans–reactive Th17 cells that travel between oral and gut mucosa and become more pathogenic in Crohn’s disease, suggesting a fungal–immune link that could matter for disease mechanisms...

The study identifies a previously unrecognized protein (TNFAIP1) that appears to promote inflammation in ulcerative colitis and proposes a compound (Salidroside) that directly binds and inhibits it in lab and mouse...

New targeted delivery approaches aim to concentrate therapy in the gut lining and inflamed areas, which could improve effectiveness and reduce systemic side effects for people with IBD.

This review collects preclinical evidence that a traditional Chinese medicine formula (Gegen Qinlian Decoction) may act on inflammation, the gut barrier, immunity, and microbiota — all relevant to ulcerative colitis and...

Macrophages and innate immune signaling are central to how gut inflammation starts and persists in IBD; better understanding these pathways could point to new treatment strategies for people whose disease doesn’t fully...

People with IBD may have overlapping genetic and cellular features with other autoimmune liver diseases like primary biliary cholangitis; understanding shared biology could eventually improve disease monitoring or point...

The study describes a new oral-delivery microsphere that improved loading and gut-targeted release of celastrol and showed beneficial effects in a mouse colitis model and on gut microbiota. If translatable, this approach...

Cure8 found this source from Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, but the page could not be read reliably yet. It is tagged...

The study synthesizes many stool metagenomes to find consistent microbial species, functional pathways, and strain-level differences linked to IBD and to distinctions between Crohn’s disease and ulcerative...

If you have ulcerative colitis, the study suggests that TCM pattern labels (DCSR vs PXSY) align with measurable differences in inflammation and tissue damage, which could influence personalized symptom assessment or...

Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...

This study identifies a plant-derived polysaccharide (from the stem of Dendrobium huoshanense) that reduced inflammation and tissue injury in a mouse model of ulcerative colitis and points to GLP-1 signaling as a likely...

This study points to a specific immune pathway (IRF5 repressing S100A9) that controls suppressive granulocytic MDSCs in ulcerative colitis, suggesting a new target for therapies aimed at modulating harmful inflammation.

Nanoparticle technologies could eventually enable more targeted drug delivery and improved imaging for IBD and related GI diseases, which may lead to better diagnosis and less systemic side effects. However, translation...